NCT02323269 - Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Multiple Sclerosis, Relapsing-RemittingRelapsing-Remitting Multiple Sclerosis

Interventions

DRUG

dimethyl fumarate

administered according to the local product label (i.e., Canadian Product Monograph).

Trial Locations (10)

Research Site, Edmonton

Research Site, Burnaby

Research Site, Saint John

Research Site, St. John's

Research Site, Halifax

Research Site, Sydney

Research Site, Cambridge

Research Site, London

Research Site, Gatineau

Research Site, Montreal